Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexei Grom

Pediatric Rheumatology Cincinnati, OH Medical Doctor

NPI 1619997715 CMS profile 254592

3333 Burnet Ave, Ml 4010, Cincinnati, OH 45229

Open in the dashboard

General payments

$63,001

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$856,513 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Alexei Grom of Cincinnati, OH is reported in the CMS Open Payments database as having received $63,001 across 86 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $856,513 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pediatric Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,185 15
2024 General $21,073 21
2023 General $19,674 22
2022 General $2,911 4
2021 General $2,921 2
2020 General $2,164 5
2019 General $6,074 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexei Grom
  • Pediatric Rheumatology median
  • Middle half of Pediatric Rheumatology
  • National median

In program year 2025, general payments to Alexei Grom were reported at $8,185. Among 204 Pediatric Rheumatology profiles paid that year, the median was $146 and the middle half received between $95 and $522.

Show as a table
Year Alexei Grom Pediatric Rheumatology median Middle half National median
2019 $6,074 $141 $61–$1,029 $163
2020 $2,164 $113 $33–$419 $114
2021 $2,921 $189 $61–$1,640 $132
2022 $2,911 $120 $28–$404 $149
2023 $19,674 $97 $41–$222 $160
2024 $21,073 $139 $48–$606 $164
2025 $8,185 $146 $95–$522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sobi, Inc $31,384 24 payments
  2. Swedish Orphan Biovitrum AB $21,222 5 payments
  3. Novartis Pharmaceuticals Corporation $7,708 30 payments
  4. Kiniksa Pharmaceuticals International, plc $2,200 1 payment
  5. AbbVie, Inc. $256 12 payments
  6. Amgen Inc. $104 6 payments
  7. GlaxoSmithKline, LLC. $31 2 payments
  8. E.R. Squibb & Sons, L.L.C. $31 2 payments
  9. CutisPharma, Inc. $17 1 payment
  10. Genentech USA, Inc. $16 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $36,605 12 payments
  2. Travel and Lodging $13,317 9 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,746 3 payments
  4. Food and Beverage $2,333 62 payments
Products named General payments · program years 2019–2025
  1. GAMIFANT $30,574 20 payments
  2. COSENTYX $2,921 2 payments
  3. Arcalyst $2,200 1 payment
  4. SYNAGIS $398 1 payment
  5. ILARIS Immunology $343 14 payments
  6. RINVOQ $160 7 payments
  7. HUMIRA $110 6 payments
  8. ILARIS Immunology $83 3 payments
  9. ILARIS Immunology $52 3 payments
  10. Enbrel $48 3 payments
  11. Other $239 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Rheumatology: 1,511

Drug cost

$224

Median for Rheumatology: $1,139,948

Branded share of claims

100%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methotrexate Methotrexate Sodium Brand 16 $224

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $2,200
$2,200 — —
SYNAGIS
  • Sobi, Inc $398
$398 — —
ILARIS
  • Novartis Pharmaceuticals Corporation $117
$117 — —
RINVOQ
  • AbbVie, Inc. $99
$99 — —
XELJANZ
  • PFIZER INC. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Rheumatology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record